{
  "url": "https://finance.yahoo.com/news/high-growth-tech-stocks-europe-054510215.html",
  "authorsByline": "Simply Wall St",
  "articleId": "a3a6b310e1f04c7b91dd8ad7e93787a2",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/simply_wall_st__316/8e4ccfff9d65315feb5142c582659a19",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-25T05:45:10+00:00",
  "addDate": "2025-08-25T05:59:28.649753+00:00",
  "refreshDate": "2025-08-25T05:59:28.649755+00:00",
  "score": 1.0,
  "title": "High Growth Tech Stocks in Europe Featuring Three Prominent Companies",
  "description": "The European market has recently experienced a positive shift, with the pan-European STOXX Europe 600 Index climbing 1.40% amid optimism surrounding potential U.S. rate cuts and a rise in business activity across the eurozone. In this environment, identifying high-growth tech stocks involves looking for companies that can capitalize on expanding business activity and demonstrate resilience amidst fluctuating consumer confidence and economic conditions.",
  "content": "The European market has recently experienced a positive shift, with the pan-European STOXX Europe 600 Index climbing 1.40% amid optimism surrounding potential U.S. rate cuts and a rise in business activity across the eurozone. In this environment, identifying high-growth tech stocks involves looking for companies that can capitalize on expanding business activity and demonstrate resilience amidst fluctuating consumer confidence and economic conditions. Click here to see the full list of 53 stocks from our European High Growth Tech and AI Stocks screener. Here's a peek at a few of the choices from the screener. Overview: Oryzon Genomics S.A. is a clinical stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and CNS disorders, with a market cap of \u20ac213.55 million. Operations: Oryzon Genomics S.A. generates revenue primarily from its biotechnology segment, amounting to \u20ac7.47 million. The company focuses on developing therapeutics based on epigenetics for cancer and central nervous system disorders. Oryzon Genomics is poised for significant growth with an expected revenue increase of 56% annually, outpacing the broader Spanish market's 4.3%. This biotech firm is navigating toward profitability with anticipated earnings growth of 58.89% per year over the next three years, reflecting its robust pipeline and innovative R&D efforts. Recent advancements include FDA discussions for their Phase III trial of vafidemstat in Borderline Personality Disorder, highlighting Oryzon's commitment to addressing unmet medical needs through epigenetic therapies. Despite current unprofitability and a volatile share price, these strategic moves could position Oryzon favorably in a competitive biotech landscape.\n\u2022 Dive into the specifics of Oryzon Genomics here with our thorough health report.\n\u2022 Examine Oryzon Genomics' past performance report to understand how it has performed in the past. BME:ORY Earnings and Revenue Growth as at Aug 2025 Overview: LINK Mobility Group Holding ASA, along with its subsidiaries, offers mobile and communication-platform-as-a-service solutions and has a market cap of NOK9.41 billion.",
  "medium": "Article",
  "links": [
    "https://simplywall.st/portfolio?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014256",
    "https://simplywall.st/company/id/c0cada85-1f49-4417-844d-4b7fa7d2b365/past?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014256",
    "https://simplywall.st/company/id/c0cada85-1f49-4417-844d-4b7fa7d2b365?utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo&blueprint=4014256",
    "https://simplywall.st/company/id/dd17423e-9c88-41ae-8c34-5047e7a2ea7f?utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo&blueprint=4014256",
    "https://simplywall.st/discover/investing-ideas/152/undiscovered-gems-with-strong-fundamentals/global?utm_medium=finance_user&utm_campaign=conclusion-grid&utm_source=yahoo&blueprint=4014256",
    "https://simplywall.st/discover/investing-ideas/215171/high-growth-tech-and-ai-stocks/global?utm_medium=finance_user&utm_campaign=conclusion-grid&utm_source=yahoo&blueprint=4014256",
    "https://simplywall.st/discover/investing-ideas/10228/fast-growing-stocks-with-high-insider-ownership/global?utm_medium=finance_user&utm_campaign=conclusion-grid&utm_source=yahoo&blueprint=4014256",
    "https://feedback.simplywall.st/article/NDAxNDI1NjowZDQ1YmI4ZDg0YTQ2ZDBm",
    "https://simplywall.st/company/id/dd17423e-9c88-41ae-8c34-5047e7a2ea7f/past?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014256",
    "https://simplywall.st/company/id/c47ea9d4-3143-40e7-81a3-3dab1a02d3a5?utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo&blueprint=4014256",
    "https://simplywall.st/company/id/c47ea9d4-3143-40e7-81a3-3dab1a02d3a5/past?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014256",
    "https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows/global?utm_medium=finance_user&utm_campaign=conclusion-grid&utm_source=yahoo&blueprint=4014256"
  ],
  "labels": [],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "Oryzon Genomics S.A.",
      "weight": 0.09975527
    },
    {
      "name": "Oryzon Genomics",
      "weight": 0.099686444
    },
    {
      "name": "High Growth Tech Stocks",
      "weight": 0.09117348
    },
    {
      "name": "Revenue Growth",
      "weight": 0.08903056
    },
    {
      "name": "anticipated earnings growth",
      "weight": 0.082918935
    },
    {
      "name": "Oryzon",
      "weight": 0.080335155
    },
    {
      "name": "significant growth",
      "weight": 0.07650664
    },
    {
      "name": "business activity",
      "weight": 0.06520346
    },
    {
      "name": "European High Growth Tech",
      "weight": 0.06452472
    },
    {
      "name": "Oryzon Genomics past performance report",
      "weight": 0.06428305
    }
  ],
  "topics": [
    {
      "name": "Markets"
    }
  ],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.97900390625
    },
    {
      "name": "/News/Business News/Company News",
      "score": 0.9658203125
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.9580078125
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.74755859375
    }
  ],
  "sentiment": {
    "positive": 0.82179105,
    "negative": 0.019402314,
    "neutral": 0.15880662
  },
  "summary": "The European market has seen a positive trend, with the pan-European STOXX Europe 600 Index climbing 1.40% and the rise in business activity across the eurozone. Oryzon Genomics S.A. is a clinical stage biopharmaceutical company focused on developing epigenetic therapies for cancer and central nervous system disorders. The company is expected to generate a 56% annual revenue increase, outpacing the broader Spanish market's 4.3%. Despite unprofitability and a volatile share price, this could position them favorably in a competitive biotech landscape.",
  "shortSummary": "The European market is seeing a positive shift with strong growth, driven by Oryzon Genomics' biotechnology and LINK Mobility Group Holding ASA's mobile phone capabilities.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "3c09316931cc45e88def1e79cf249e99",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://simplywall.st/company/id/c47ea9d4-3143-40e7-81a3-3dab1a02d3a5/past?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014256",
      "text": "Oryzon Genomics Past Earnings Performance\nPast criteria checks 0/6\nOryzon Genomics's earnings have been declining at an average annual rate of -1.7%, while the Biotechs industry saw earnings growing at 18.5% annually. Revenues have been growing at an average rate of 2.4% per year.\nKey information\n-1.67%\nEarnings growth rate\n5.07%\nEPS growth rate\n| Biotechs Industry Growth | -7.17% |\n| Revenue growth rate | 2.36% |\n| Return on equity | -3.69% |\n| Net Margin | -56.48% |\n| Last Earnings Update | 30 Jun 2025 |\nRecent past performance updates\nRecent updates\nWe Think The Compensation For Oryzon Genomics S.A.'s (BME:ORY) CEO Looks About Right\nJun 20Insufficient Growth At Oryzon Genomics S.A. (BME:ORY) Hampers Share Price\nFeb 13Growth Investors: Industry Analysts Just Upgraded Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts By 54%\nOct 03Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch\nJun 09Is Oryzon Genomics (BME:ORY) Using Too Much Debt?\nApr 04Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts\nJul 24Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?\nMay 01Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?\nFeb 26If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns\nJan 04Revenue & Expenses Breakdown\nHow Oryzon Genomics makes and spends money. Based on latest reported earnings, on an LTM basis.\nEarnings and Revenue History\n| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |\n|---|---|---|---|---|\n| 30 Jun 25 | 7 | -4 | 4 | 0 |\n| 31 Mar 25 | 7 | -4 | 4 | 0 |\n| 31 Dec 24 | 7 | -4 | 4 | 0 |\n| 30 Sep 24 | 14 | -4 | 4 | -5 |\n| 30 Jun 24 | 11 | -4 | 4 | 0 |\n| 31 Mar 24 | 14 | -3 | 3 | -2 |\n| 31 Dec 23 | 14 | -3 | 4 | 0 |\n| 30 Sep 23 | 16 | -4 | 3 | 0 |\n| 30 Jun 23 | 16 | -4 | 3 | 0 |\n| 31 Mar 23 | 16 | -4 | 3 | 0 |\n| 31 Dec 22 | 16 | -4 | 4 | 0 |\n| 30 Sep 22 | 11 | -4 | 4 | 1 |\n| 30 Jun 22 | 13 | -5 | 3 | 0 |\n| 31 Mar 22 | 11 | -4 | 4 | 0 |\n| 31 Dec 21 | 11 | -5 | 4 | 0 |\n| 30 Sep 21 | 10 | -4 | 5 | 1 |\n| 30 Jun 21 | 9 | -3 | 4 | 0 |\n| 31 Mar 21 | 6 | -4 | 4 | 4 |\n| 31 Dec 20 | 10 | -3 | 4 | 0 |\n| 30 Sep 20 | 10 | -3 | 4 | 0 |\n| 30 Jun 20 | 12 | -3 | 4 | 0 |\n| 31 Mar 20 | 12 | -4 | 3 | 0 |\n| 31 Dec 19 | 10 | -4 | 3 | 0 |\n| 30 Sep 19 | 9 | -3 | 3 | 0 |\n| 30 Jun 19 | 8 | -3 | 3 | 0 |\n| 31 Mar 19 | 7 | -1 | 3 | 0 |\n| 31 Dec 18 | 7 | -1 | 3 | 0 |\n| 30 Sep 18 | 6 | -2 | 3 | 0 |\n| 30 Jun 18 | 5 | -2 | 3 | 0 |\n| 31 Mar 18 | 5 | -5 | 3 | 0 |\n| 31 Dec 17 | 4 | -5 | 3 | 0 |\n| 30 Sep 17 | 5 | -5 | 3 | 0 |\n| 30 Jun 17 | 5 | -5 | 3 | 0 |\n| 31 Mar 17 | 5 | -6 | 3 | 0 |\n| 31 Dec 16 | 5 | -5 | 3 | 0 |\n| 30 Sep 16 | 5 | -5 | 3 | 0 |\n| 30 Jun 16 | 5 | -4 | 2 | 0 |\n| 31 Mar 16 | 7 | -1 | 2 | 0 |\n| 31 Dec 15 | 7 | -1 | 2 | 0 |\n| 30 Sep 15 | 7 | -1 | 2 | 0 |\n| 30 Jun 15 | 6 | -1 | 2 | 0 |\n| 31 Mar 15 | 10 | 2 | 2 | 0 |\n| 31 Dec 14 | 16 | 7 | 2 | 0 |\nQuality Earnings: ORY is currently unprofitable.\nGrowing Profit Margin: ORY is currently unprofitable.\nFree Cash Flow vs Earnings Analysis\nPast Earnings Growth Analysis\nEarnings Trend: ORY is unprofitable, and losses have increased over the past 5 years at a rate of 1.7% per year.\nAccelerating Growth: Unable to compare ORY's earnings growth over the past year to its 5-year average as it is currently unprofitable\nEarnings vs Industry: ORY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (71.7%).\nReturn on Equity\nHigh ROE: ORY has a negative Return on Equity (-3.69%), as it is currently unprofitable.\nReturn on Assets\nReturn on Capital Employed\nDiscover strong past performing companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/25 04:50 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nOryzon Genomics S.A. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Jyoti Prakash | Edison Investment Research |\n| Arron Aatkar | Edison Investment Research |\n| Joaquin Garcia-Quiros | JB Capital Markets |"
    },
    {
      "url": "https://simplywall.st/discover/investing-ideas/10228/fast-growing-stocks-with-high-insider-ownership/global?utm_medium=finance_user&utm_campaign=conclusion-grid&utm_source=yahoo&blueprint=4014256",
      "text": "Results\n1374\nCompanies with strong growth potential, backed by optimistic outlooks both from analysts and management.\n1374 companies\nFulin Precision\nMarket Cap: CN\u00a526.5b\nEngages in the research and development, manufacture, and sale of automotive engine parts in China.\n300432\nCN\u00a515.51\n7D\n-1.1%\n1Y\n235.6%\nSynspective\nMarket Cap: JP\u00a594.5b\nDesigns, builds, and operates a fleet of synthetic aperture radar satellites (SAR) to detect and understand changes.\n290A\nJP\u00a5847.00\n7D\n-12.8%\n1Y\nn/a\nGold Circuit Electronics\nMarket Cap: NT$223.4b\nDesigns, manufactures, processes, and distributes printed circuit boards in Taiwan.\n2368\nNT$459.00\n7D\n-1.4%\n1Y\n112.5%\nFindi\nMarket Cap: AU$239.2m\nThrough its subsidiaries, engages in the development of digital payment systems in India.\nFND\nAU$3.87\n7D\n-3.5%\n1Y\n-5.1%\nNovoray\nMarket Cap: CN\u00a514.6b\nProvides industrial powder materials for various applications in China and internationally.\n688300\nCN\u00a560.54\n7D\n3.6%\n1Y\n92.9%\nLaopu Gold\nMarket Cap: HK$125.8b\nDesigns, manufactures, and sells jewelry products in Mainland China, Hong Kong, and Macau.\n6181\nHK$728.50\n7D\n-6.6%\n1Y\n686.7%\nCyclopharm\nMarket Cap: AU$108.9m\nCyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally.\nCYC\nAU$0.98\n7D\n-5.8%\n1Y\n-30.2%\nElliptic Laboratories\nMarket Cap: NOK 1.2b\nAn artificial intelligence (AI) software company, engages in the provision of AI virtual smart sensors for the smartphone, laptop, Internet of Things, and automotive markets in Norway, the United States, China, South Korea, Taiwan, and Japan.\nELABS\nNOK 11.06\n7D\n-7.8%\n1Y\n-10.7%\nPharma Mar\nMarket Cap: \u20ac1.4b\nA biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally.\nPHM\n\u20ac82.45\n7D\n-2.5%\n1Y\n101.7%\nAscentage Pharma Group International\nMarket Cap: HK$33.7b\nA clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.\n6855\nHK$90.65\n7D\n5.3%\n1Y\n215.9%\nCredo Technology Group Holding\nMarket Cap: US$19.6b\nProvides various high-speed connectivity solutions for optical and electrical Ethernet, and PCIe applications in the United States, Taiwan, Mainland China, Hong Kong, and internationally.\nCRDO\nUS$114.04\n7D\n-4.0%\n1Y\n223.9%\nPropel Holdings\nMarket Cap: CA$1.3b\nOperates as a financial technology company.\nPRL\nCA$32.76\n7D\n-0.06%\n1Y\n17.4%\nCD Projekt\nMarket Cap: z\u014225.8b\nTogether its subsidiaries, engages in the development, publishing, and digital distribution of video games for personal computers and video game consoles in Poland.\nCDR\nz\u0142257.90\n7D\n1.1%\n1Y\n43.1%\nKebNi\nMarket Cap: SEK 688.7m\nDevelops, produces, and sells products and applications for stabilization, navigation, and satcom worldwide.\nKEBNI B\nSEK 2.54\n7D\n17.1%\n1Y\n76.6%\nHesai Group\nMarket Cap: US$3.1b\nThrough with its subsidiaries, engages in the development, manufacture, and sale of three-dimensional light detection and ranging solutions (LiDAR) in Mainland China, Europe, North America, and internationally.\nHSAI\nUS$23.26\n7D\n-9.1%\n1Y\n445.4%\nNewfield Resources\nMarket Cap: AU$83.7m\nEngages in the mine development, stope mining, and mineral exploration activities in Australia and Africa.\nNWF\nAU$0.089\n7D\n0%\n1Y\n-19.1%\nM31 Technology\nMarket Cap: NT$19.7b\nProvides silicon intellectual property (IP) design services in the integrated circuit industry.\n6643\nNT$472.50\n7D\n-5.9%\n1Y\n-53.2%\nImage Resources\nMarket Cap: AU$88.1m\nEngages in the production and exploration of mineral sands in Western Australia.\nIMA\nAU$0.079\n7D\n0%\n1Y\n8.2%\nVuno\nMarket Cap: \u20a9291.9b\nOperates as a medical artificial intelligence (AI) solution development company.\nA338220\n\u20a920,850.00\n7D\n4.0%\n1Y\n-44.4%\nAprilBioLtd\nMarket Cap: \u20a9474.2b\nAprilBio Co., Ltd. develops long-acting type biobetter and antibody biologics.\nA397030\n\u20a921,050.00\n7D\n-2.3%\n1Y\n1.7%\nSuzhou Sunmun Technology\nMarket Cap: CN\u00a54.6b\nEngages in the research, production, and sale of nano-coloring materials, functional nano-dispersions, special additives, intelligent color matching systems, and electronic chemicals in China.\n300522\nCN\u00a514.24\n7D\n-0.8%\n1Y\n54.4%\nKrishna Institute of Medical Sciences\nMarket Cap: \u20b9294.8b\nProvides medical and health care services under the KIMS Hospitals brand in India.\nKIMS\n\u20b9736.80\n7D\n-1.1%\n1Y\n49.1%\nAnand Rathi Wealth\nMarket Cap: \u20b9233.0b\nProvides financial advisory, brokerage, and consultancy services in India.\nANANDRATHI\n\u20b92,806.20\n7D\n3.5%\n1Y\n55.7%\nFenix Resources\nMarket Cap: AU$227.0m\nEngages in the exploration, development, and mining of mineral tenements in Western Australia.\nFEX\nAU$0.30\n7D\n-7.6%\n1Y\n0%\nOscotec\nMarket Cap: \u20a91.2t\nOperates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses.\nA039200\n\u20a932,600.00\n7D\n-5.5%\n1Y\n-18.4%\nZhejiang Leapmotor Technology\nMarket Cap: HK$99.9b\nEngages in the research and development, production, and sale of new energy vehicles in Mainland China and internationally.\n9863\nHK$71.00\n7D\n8.6%\n1Y\n249.8%\nHippo Holdings\nMarket Cap: US$844.7m\nProvides property and casualty insurance products to individuals and business customers primarily in the United States.\nHIPO\nUS$33.75\n7D\n6.7%\n1Y\n70.0%\nTechwing\nMarket Cap: \u20a91.0t\nDevelops, manufactures, sells, and services semiconductor inspection equipment in South Korea and internationally.\nA089030\n\u20a928,850.00\n7D\n-1.2%\n1Y\n-37.1%\nBinastra Corporation Berhad\nMarket Cap: RM 1.9b\nAn investment holding company, engages in general contractor and property developer, building and civil engineering works in turnkey projects in Malaysia.\nBNASTRA\nRM 1.78\n7D\n0.6%\n1Y\n44.7%\nSineng ElectricLtd\nMarket Cap: CN\u00a512.3b\nEngages in the research and development, manufacture, maintenance, and trading of power electronic products in the People's Republic of China and internationally.\n300827\nCN\u00a524.59\n7D\n-0.04%\n1Y\n12.2%\nSamyang Foods\nMarket Cap: \u20a910.7t\nEngages in the food business in South Korea and internationally.\nA003230\n\u20a91,438,000.00\n7D\n4.2%\n1Y\n187.6%\nMarinomed Biotech\nMarket Cap: \u20ac35.2m\nA biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally.\nMARI\n\u20ac19.80\n7D\n1.0%\n1Y\n253.6%\nBergen Carbon Solutions\nMarket Cap: NOK 187.6m\nOperates as a clean carbon technology and materials company in Norway.\nBCS\nNOK 4.47\n7D\n-6.7%\n1Y\n-12.4%\nENGAGE XR Holdings\nMarket Cap: UK\u00a35.4m\nEngages in the development of the educational virtual reality platform.\nEXR\nUK\u00a30.01\n7D\n0%\n1Y\n17.1%\nCircus\nMarket Cap: \u20ac402.0m\nA technology company, develops and delivers autonomous solutions for the food service market.\nCA1\n\u20ac16.90\n7D\n-12.7%\n1Y\n-21.8%\nAtour Lifestyle Holdings\nMarket Cap: US$4.9b\nThrough its subsidiaries, develops lifestyle brands around hotel offerings in the People\u2019s Republic of China.\nATAT\nUS$35.73\n7D\n2.4%\n1Y\n103.9%"
    },
    {
      "url": "https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows/global?utm_medium=finance_user&utm_campaign=conclusion-grid&utm_source=yahoo&blueprint=4014256",
      "text": "Results\n860\nCompanies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.\n860 companies\nAmbipar Participa\u00e7\u00f5es e Empreendimentos\nMarket Cap: R$22.3b\nAmbipar Participa\u00e7\u00f5es e Empreendimentos S.A.\nAMBP3\nR$13.40\n7D\n-4.8%\n1Y\n45.9%\nKolmar Korea\nMarket Cap: \u20a91.9t\nResearches, develops, produces, and sells beauty and health products in South Korea and internationally.\nA161890\n\u20a979,100.00\n7D\n-0.8%\n1Y\n12.8%\nWELL Health Technologies\nMarket Cap: CA$1.2b\nOperates as a practitioner-focused digital healthcare company in Canada, the United States, and internationally.\nWELL\nCA$4.92\n7D\n-1.6%\n1Y\n6.5%\nBloomberry Resorts\nMarket Cap: \u20b141.0b\nThrough its subsidiaries, develops, owns, and operates hotels, casinos, and integrated resorts in the Philippines and Korea.\nBLOOM\n\u20b13.57\n7D\n-0.8%\n1Y\n-53.6%\nS Chand\nMarket Cap: \u20b97.0b\nS Chand and Company Limited, an education content company, develops and delivers content, solutions, and services for the early learning, K-12, and higher education segments in India.\nSCHAND\n\u20b9197.85\n7D\n1.9%\n1Y\n-14.2%\nWanguo Gold Group\nMarket Cap: HK$32.0b\nAn investment holding company, engages in mining, ore processing, and sale of concentrate products in the People\u2019s Republic of China and Solomon Islands.\n3939\nHK$29.50\n7D\n-16.2%\n1Y\n282.1%\nSavaria\nMarket Cap: CA$1.5b\nProvides accessibility solutions for the elderly and physically challenged people in Canada, the United States, Europe, and internationally.\nSIS\nCA$21.15\n7D\n0.5%\n1Y\n5.6%\nWix.com\nMarket Cap: US$7.4b\nOperates a cloud-based web development platform for registered users and creators worldwide.\nWIX\nUS$131.82\n7D\n2.4%\n1Y\n-20.6%\nKeePer Technical Laboratory\nMarket Cap: JP\u00a594.0b\nDevelops, manufactures, and sells car coatings, car washing chemicals and equipment, and other products in Japan.\n6036\nJP\u00a53,445.00\n7D\n-1.3%\n1Y\n-7.9%\nNorconsult\nMarket Cap: NOK 14.2b\nProvides consultancy services with focus on community planning, engineering design, and architecture in the Nordics and internationally.\nNORCO\nNOK 45.80\n7D\n6.9%\n1Y\n32.9%\nCosmax\nMarket Cap: \u20a92.4t\nResearches, develops, produces, and manufactures cosmetic and health function food products in Korea and internationally.\nA192820\n\u20a9213,000.00\n7D\n12.0%\n1Y\n75.5%\nMatsuya R&DLtd\nMarket Cap: JP\u00a515.4b\nDevelops, manufactures, and sells stitching systems for automobile safety devices in Japan.\n7317\nJP\u00a5720.00\n7D\n2.1%\n1Y\n9.4%\nCorporativo Fragua. de\nMarket Cap: Mex$51.3b\nOperates pharmacy stores under the Superfarmacia name in Mexico.\nFRAGUA B\nMex$536.00\n7D\n0.006%\n1Y\n-45.5%\nUWC Berhad\nMarket Cap: RM 3.0b\nAn investment holding company, engages in the provision of precision sheet metal fabrication, precision machined components, and value-added assembly services.\nUWC\nRM 2.71\n7D\n-1.5%\n1Y\n0.7%\nHillgrove Resources\nMarket Cap: AU$96.7m\nEngages in the operation, exploration, and development of mineral properties in Australia.\nHGO\nAU$0.037\n7D\n5.7%\n1Y\n-33.9%\nInvestar Holding\nMarket Cap: US$230.2m\nOperates as the bank holding company for Investar Bank that provides a range of commercial banking products to individuals, professionals, and small to medium-sized businesses in south Louisiana, southeast Texas, and Alabama in the United States.\nISTR\nUS$23.42\n7D\n6.4%\n1Y\n27.8%\nFaraday Technology\nMarket Cap: NT$38.8b\nOperates as a fabless ASIC/SoC and silicon intellectual property (IP) provider in China, Taiwan, Japan, the United States, and internationally.\n3035\nNT$149.00\n7D\n-2.9%\n1Y\n-49.8%\nJiangxi Rimag Group\nMarket Cap: HK$7.0b\nInvests and operates medical imaging centers in China.\n2522\nHK$19.11\n7D\n-18.0%\n1Y\n5.1%\nSolarEdge Technologies\nMarket Cap: US$2.0b\nDesigns, develops, manufactures, and sells direct current (DC) optimized inverter systems for solar photovoltaic (PV) installations in the United States, Germany, the Netherlands, Italy, rest of Europe, and internationally.\nSEDG\nUS$34.30\n7D\n10.1%\n1Y\n31.3%\nATON Green Storage\nMarket Cap: \u20ac15.6m\nEngages in the production and sale of storage systems for photovoltaic systems and battery energy storage system.\nATON\n\u20ac2.08\n7D\n1.0%\n1Y\n-64.4%\nHypera\nMarket Cap: R$15.0b\nOperates as a pharmaceutical company in Brazil.\nHYPE3\nR$23.75\n7D\n4.1%\n1Y\n-23.5%\nReckon\nMarket Cap: AU$68.5m\nProvides software solutions in Australia, New Zealand, the United States, and internationally.\nRKN\nAU$0.60\n7D\n-4.0%\n1Y\n18.6%\nSunjin Beauty ScienceLtd\nMarket Cap: \u20a9128.1b\nSUNJIN BEAUTY SCIENCE Co. ,Ltd. researches, develops, manufactures, and exports cosmetics, surfactant, and polymer bead products.\nA086710\n\u20a910,670.00\n7D\n-4.4%\n1Y\n-3.8%\nPeapack-Gladstone Financial\nMarket Cap: US$498.5m\nOperates as the bank holding company for Peapack Private Bank & Trust that provides private banking and wealth management services in the United States.\nPGC\nUS$28.46\n7D\n7.2%\n1Y\n1.2%\nABO Energy GmbH KGaA\nMarket Cap: \u20ac337.5m\nDevelops renewable energy projects in Germany and internationally.\nAB9\n\u20ac36.60\n7D\n-4.4%\n1Y\n-21.8%\nMetropolitan Bank Holding\nMarket Cap: US$801.6m\nOperates as the bank holding company for Metropolitan Commercial Bank that provides a range of business, commercial, and retail banking products and services.\nMCB\nUS$76.92\n7D\n5.4%\n1Y\n47.6%\nAquila Part Prod Com\nMarket Cap: RON 1.7b\nProvides distribution and logistics services in Romania, Moldova, Poland, the Netherlands, Germany, and internationally.\nAQ\nRON 1.46\n7D\n1.3%\n1Y\n3.8%\nRobit Oyj\nMarket Cap: \u20ac24.4m\nEngages in the design, manufacture, and sale of drilling consumables for mining, quarrying, construction, and well drilling industries in Finland.\nROBIT\n\u20ac1.16\n7D\n-3.3%\n1Y\n-31.4%\nLATAM Airlines Group\nMarket Cap: CL$13.7t\nProvides passenger and cargo air transportation services in Chile, Argentina, Peru, Colombia, Ecuador, Brazil, the United States, other Latin American countries, the Caribbean, Europe, and Oceania.\nLTM\nCL$23.09\n7D\n9.0%\n1Y\n96.2%\nHonkarakenne Oyj\nMarket Cap: \u20ac16.9m\nDesigns, manufactures, and sells log and solid-wood house packages in Finland.\nHONBS\n\u20ac2.87\n7D\n4.0%\n1Y\n-0.3%\nApotea\nMarket Cap: SEK 11.2b\nOperates an online pharmacy in Sweden.\nAPOTEA\nSEK 107.22\n7D\n-4.1%\n1Y\nn/a\nAtea\nMarket Cap: NOK 16.3b\nProvides IT infrastructure and related solutions for businesses and public sector organizations in the Nordic countries and Baltic regions.\nATEA\nNOK 146.20\n7D\n1.2%\n1Y\n1.4%\nSRE Holdings\nMarket Cap: JP\u00a549.4b\nEngages in the AI cloud and consulting, and real estate tech businesses in Japan.\n2980\nJP\u00a53,070.00\n7D\n-5.4%\n1Y\n-33.0%\nCustomers Bancorp\nMarket Cap: US$2.2b\nOperates as the bank holding company for Customers Bank that provides banking products and services.\nCUBI\nUS$68.72\n7D\n4.3%\n1Y\n34.7%\nAustal\nMarket Cap: AU$2.9b\nEngages in the design, manufacture, and support of vessels for commercial and defense customers worldwide.\nASB\nAU$6.81\n7D\n0.7%\n1Y\n204.0%\nSantos Brasil Participa\u00e7\u00f5es\nMarket Cap: R$12.3b\nProvides port container handling and logistics services in Brazil.\nSTBP3\nR$14.18\n7D\n0.5%\n1Y\n8.1%"
    },
    {
      "url": "https://simplywall.st/company/id/dd17423e-9c88-41ae-8c34-5047e7a2ea7f/past?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014256",
      "text": "LINK Mobility Group Holding Past Earnings Performance\nPast criteria checks 1/6\nLINK Mobility Group Holding has been growing earnings at an average annual rate of 53.5%, while the Software industry saw earnings growing at 36.3% annually. Revenues have been growing at an average rate of 16.4% per year. LINK Mobility Group Holding's return on equity is 2%, and it has net margins of 1.6%.\nKey information\n53.52%\nEarnings growth rate\n56.45%\nEPS growth rate\n| Software Industry Growth | 52.55% |\n| Revenue growth rate | 16.35% |\n| Return on equity | 1.98% |\n| Net Margin | 1.57% |\n| Next Earnings Update | 05 Nov 2025 |\nRecent past performance updates\nLINK Mobility Group Holding's (OB:LINK) Performance Is Even Better Than Its Earnings Suggest\nFeb 21LINK Mobility Group Holding's (OB:LINK) Earnings Are Of Questionable Quality\nAug 22Recent updates\nLINK Mobility Group Holding ASA's (OB:LINK) P/E Is On The Mark\nAug 10LINK Mobility Group Holding ASA's (OB:LINK) Price In Tune With Earnings\nApr 17Is There An Opportunity With LINK Mobility Group Holding ASA's (OB:LINK) 47% Undervaluation?\nMar 11LINK Mobility Group Holding's (OB:LINK) Performance Is Even Better Than Its Earnings Suggest\nFeb 21Is LINK Mobility Group Holding (OB:LINK) Using Too Much Debt?\nFeb 15AI-driven SaaS Expansion Into Europe May Boost Future Earnings, But Volatility Remains A Concern\nExpansion into less penetrated European markets and terminating low-margin contracts may drive future revenue and improve net margins.An Intrinsic Calculation For LINK Mobility Group Holding ASA (OB:LINK) Suggests It's 28% Undervalued\nNov 06LINK Mobility Group Holding's (OB:LINK) Earnings Are Of Questionable Quality\nAug 22LINK Mobility Group Holding (OB:LINK) Seems To Use Debt Quite Sensibly\nAug 16These 4 Measures Indicate That LINK Mobility Group Holding (OB:LINK) Is Using Debt Reasonably Well\nFeb 02Is Now An Opportune Moment To Examine LINK Mobility Group Holding ASA (OB:LINK)?\nJan 25Shareholders Can Be Confident That LINK Mobility Group Holding's (OB:LINK) Earnings Are High Quality\nAug 23Are Investors Undervaluing LINK Mobility Group Holding ASA (OB:LINK) By 39%?\nAug 05Earnings Release: Here's Why Analysts Cut Their LINK Mobility Group Holding ASA (OB:LINK) Price Target To kr27.00\nFeb 13Industry Analysts Just Made An Upgrade To Their LINK Mobility Group Holding ASA (OB:LINK) Revenue Forecasts\nAug 18Calculating The Intrinsic Value Of LINK Mobility Group Holding ASA (OB:LINK)\nJul 18Revenue & Expenses Breakdown\nHow LINK Mobility Group Holding makes and spends money. Based on latest reported earnings, on an LTM basis.\nEarnings and Revenue History\n| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |\n|---|---|---|---|---|\n| 30 Jun 25 | 6,915 | 109 | 30 | 0 |\n| 31 Mar 25 | 6,973 | 167 | 28 | 0 |\n| 31 Dec 24 | 6,994 | 172 | 14 | 0 |\n| 30 Sep 24 | 6,941 | 176 | 38 | 0 |\n| 30 Jun 24 | 6,880 | 178 | 25 | 0 |\n| 31 Mar 24 | 6,621 | 104 | 18 | 0 |\n| 31 Dec 23 | 6,282 | 38 | 11 | 0 |\n| 30 Sep 23 | 5,909 | -263 | 57 | 0 |\n| 30 Jun 23 | 5,541 | -242 | 47 | 0 |\n| 31 Mar 23 | 5,073 | -216 | 10 | 0 |\n| 31 Dec 22 | 4,914 | -194 | 13 | 0 |\n| 30 Sep 22 | 4,788 | 158 | -104 | 0 |\n| 30 Jun 22 | 4,671 | 37 | -46 | 0 |\n| 31 Mar 22 | 4,638 | -27 | 0 | 0 |\n| 31 Dec 21 | 4,410 | -78 | 19 | 0 |\n| 30 Sep 21 | 4,154 | -196 | 246 | 0 |\n| 30 Jun 21 | 3,856 | -187 | 152 | 0 |\n| 31 Mar 21 | 3,641 | -61 | 66 | 0 |\n| 31 Dec 20 | 3,539 | -328 | 11 | 0 |\n| 30 Sep 20 | 3,356 | -383 | 192 | 0 |\n| 30 Jun 20 | 3,238 | -401 | 128 | 0 |\n| 31 Mar 20 | 3,066 | -511 | 88 | 0 |\n| 31 Dec 19 | 2,890 | -233 | 8 | 0 |\n| 31 Dec 18 | 845 | -418 | 6 | 0 |\nQuality Earnings: LINK has a large one-off loss of NOK116.3M impacting its last 12 months of financial results to 30th June, 2025.\nGrowing Profit Margin: LINK's current net profit margins (1.6%) are lower than last year (2.6%).\nFree Cash Flow vs Earnings Analysis\nPast Earnings Growth Analysis\nEarnings Trend: LINK has become profitable over the past 5 years, growing earnings by 53.5% per year.\nAccelerating Growth: LINK's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.\nEarnings vs Industry: LINK had negative earnings growth (-38.9%) over the past year, making it difficult to compare to the Software industry average (12.7%).\nReturn on Equity\nHigh ROE: LINK's Return on Equity (2%) is considered low.\nReturn on Assets\nReturn on Capital Employed\nDiscover strong past performing companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/25 04:29 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nLINK Mobility Group Holding ASA is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| null null | ABG Sundal Collier |\n| Mads Strom | Danske Bank |\n| Rayan Sayyah | Danske Bank |"
    },
    {
      "url": "https://simplywall.st/company/id/c0cada85-1f49-4417-844d-4b7fa7d2b365/past?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014256",
      "text": "Synektik Sp\u00f3lka Akcyjna Past Earnings Performance\nPast criteria checks 4/6\nSynektik Sp\u00f3lka Akcyjna has been growing earnings at an average annual rate of 52.6%, while the Healthcare Services industry saw earnings growing at 0.4% annually. Revenues have been growing at an average rate of 39.3% per year. Synektik Sp\u00f3lka Akcyjna's return on equity is 48.4%, and it has net margins of 14.9%.\nKey information\n52.56%\nEarnings growth rate\n52.56%\nEPS growth rate\n| Healthcare Services Industry Growth | 16.09% |\n| Revenue growth rate | 39.31% |\n| Return on equity | 48.45% |\n| Net Margin | 14.87% |\n| Last Earnings Update | 30 Jun 2025 |\nRecent past performance updates\nSolid Earnings May Not Tell The Whole Story For Synektik Sp\u00f3lka Akcyjna (WSE:SNT)\nAug 15Synektik Sp\u00f3lka Akcyjna's (WSE:SNT) Performance Is Even Better Than Its Earnings Suggest\nAug 13Recent updates\nSolid Earnings May Not Tell The Whole Story For Synektik Sp\u00f3lka Akcyjna (WSE:SNT)\nAug 15Is Now An Opportune Moment To Examine Synektik Sp\u00f3lka Akcyjna (WSE:SNT)?\nJan 21Cardiac marker could be a hit\nIn 5 years, the company should still be thriving, entering new markets and expanding in existing ones. Positive passage of the third stage of testing of a new cardiac marker could help. Due to the natSynektik Sp\u00f3lka Akcyjna's (WSE:SNT) 25% Price Boost Is Out Of Tune With Earnings\nSep 07Does Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Deserve A Spot On Your Watchlist?\nSep 03Synektik Sp\u00f3lka Akcyjna's (WSE:SNT) Performance Is Even Better Than Its Earnings Suggest\nAug 13Broker Revenue Forecasts For Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Are Surging Higher\nJun 29Why The 44% Return On Capital At Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Should Have Your Attention\nMar 13Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Looks Just Right With A 26% Price Jump\nFeb 15Here's Why We Think Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Might Deserve Your Attention Today\nFeb 08Solid Earnings Reflect Synektik Sp\u00f3lka Akcyjna's (WSE:SNT) Strength As A Business\nJan 26Estimating The Intrinsic Value Of Synektik Sp\u00f3lka Akcyjna (WSE:SNT)\nDec 15Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Has A Rock Solid Balance Sheet\nSep 12We Like Synektik Sp\u00f3lka Akcyjna's (WSE:SNT) Returns And Here's How They're Trending\nJun 22Is Now The Time To Put Synektik Sp\u00f3lka Akcyjna (WSE:SNT) On Your Watchlist?\nMay 23Is Synektik Sp\u00f3lka Akcyjna (WSE:SNT) A Risky Investment?\nOct 04Is Synektik Sp\u00f3lka Akcyjna (WSE:SNT) A Risky Investment?\nOct 27Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Is Posting Promising Earnings But The Good News Doesn\u2019t Stop There\nJun 22These 4 Measures Indicate That Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Is Using Debt Safely\nJun 10Does Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Have A Healthy Balance Sheet?\nMar 09Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Looks Like A Good Stock, And It's Going Ex-Dividend Soon\nFeb 13Does Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Have A Place In Your Dividend Portfolio?\nJan 25Is Synektik Sp\u00f3lka Akcyjna's (WSE:SNT) Latest Stock Performance A Reflection Of Its Financial Health?\nDec 25Is Synektik Sp\u00f3lka Akcyjna (WSE:SNT) A Risky Investment?\nNov 30Revenue & Expenses Breakdown\nHow Synektik Sp\u00f3lka Akcyjna makes and spends money. Based on latest reported earnings, on an LTM basis.\nEarnings and Revenue History\n| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |\n|---|---|---|---|---|\n| 30 Jun 25 | 623 | 93 | 72 | 24 |\n| 31 Mar 25 | 593 | 83 | 66 | 23 |\n| 31 Dec 24 | 556 | 81 | 59 | 24 |\n| 30 Sep 24 | 624 | 83 | 59 | 23 |\n| 30 Jun 24 | 619 | 91 | 56 | 8 |\n| 31 Mar 24 | 596 | 76 | 54 | 11 |\n| 31 Dec 23 | 574 | 68 | 41 | 18 |\n| 30 Sep 23 | 447 | 52 | 47 | 16 |\n| 30 Jun 23 | 370 | 39 | 41 | 15 |\n| 31 Mar 23 | 304 | 26 | 38 | 13 |\n| 31 Dec 22 | 275 | 28 | 34 | 11 |\n| 30 Sep 22 | 167 | 10 | 29 | 10 |\n| 30 Jun 22 | 160 | 11 | 23 | 7 |\n| 31 Mar 22 | 140 | 11 | 19 | 7 |\n| 31 Dec 21 | 130 | 7 | 16 | 7 |\n| 30 Sep 21 | 129 | 8 | 14 | 6 |\n| 30 Jun 21 | 105 | 8 | 14 | 6 |\n| 31 Mar 21 | 112 | 10 | 13 | 5 |\n| 31 Dec 20 | 122 | 10 | 14 | 5 |\n| 30 Sep 20 | 125 | 9 | 14 | 5 |\n| 30 Jun 20 | 130 | 6 | 16 | 6 |\n| 31 Mar 20 | 125 | 5 | 17 | 5 |\n| 31 Dec 19 | 106 | 3 | 17 | 7 |\n| 30 Sep 19 | 135 | 9 | 17 | 7 |\n| 30 Jun 19 | 119 | 7 | 14 | 14 |\n| 31 Mar 19 | 113 | 8 | 13 | 15 |\n| 31 Dec 18 | 103 | 14 | 11 | 15 |\n| 30 Sep 18 | 71 | 9 | 11 | 13 |\n| 31 Mar 18 | 64 | 11 | 11 | 0 |\n| 31 Dec 17 | 63 | 4 | 11 | 0 |\n| 30 Sep 17 | 43 | 2 | 10 | 0 |\n| 30 Jun 17 | 46 | 1 | 11 | 0 |\n| 31 Mar 17 | 49 | 2 | 11 | 0 |\n| 31 Dec 16 | 49 | 1 | 11 | 0 |\n| 30 Sep 16 | 61 | 0 | 11 | 0 |\n| 30 Jun 16 | 87 | 2 | 11 | 0 |\n| 31 Mar 16 | 81 | -1 | 11 | 0 |\n| 31 Dec 15 | 84 | -1 | 11 | 0 |\n| 30 Sep 15 | 88 | 0 | 12 | 0 |\n| 30 Jun 15 | 68 | -2 | 11 | 0 |\n| 31 Mar 15 | 79 | 2 | 11 | 0 |\n| 31 Dec 14 | 78 | 3 | 11 | 0 |\n| 30 Sep 14 | 79 | 6 | 4 | 0 |\nQuality Earnings: SNT has a high level of non-cash earnings.\nGrowing Profit Margin: SNT's current net profit margins (14.9%) are higher than last year (14.8%).\nFree Cash Flow vs Earnings Analysis\nPast Earnings Growth Analysis\nEarnings Trend: SNT's earnings have grown significantly by 52.6% per year over the past 5 years.\nAccelerating Growth: SNT's earnings growth over the past year (1.3%) is below its 5-year average (52.6% per year).\nEarnings vs Industry: SNT earnings growth over the past year (1.3%) exceeded the Healthcare Services industry 1.3%.\nReturn on Equity\nHigh ROE: SNT's Return on Equity (48.4%) is considered outstanding.\nReturn on Assets\nReturn on Capital Employed\nDiscover strong past performing companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/25 04:23 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/09/30 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nSynektik Sp\u00f3lka Akcyjna is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Kamil Kliszcz | Biuro maklerskie mBanku |\n| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |\n| Mateusz Krupa | Biuro maklerskie mBanku |"
    },
    {
      "url": "https://simplywall.st/company/id/c0cada85-1f49-4417-844d-4b7fa7d2b365?utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo&blueprint=4014256",
      "text": "Synektik Sp\u00f3lka Akcyjna (SNT) Stock Overview\nProvides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 4/6 |\n| Future Growth | 5/6 |\n| Past Performance | 4/6 |\n| Financial Health | 6/6 |\n| Dividends | 2/6 |\nSNT Community Fair Values\nSee what 30 others think this stock is worth. Follow their fair value or set your own to get alerts.\nSynektik Sp\u00f3lka Akcyjna Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | z\u0142223.00 |\n| 52 Week High | z\u0142241.00 |\n| 52 Week Low | z\u0142141.20 |\n| Beta | 0.87 |\n| 1 Month Change | 4.30% |\n| 3 Month Change | -1.76% |\n| 1 Year Change | 55.51% |\n| 3 Year Change | 732.09% |\n| 5 Year Change | 799.19% |\n| Change since IPO | 2,609.60% |\nRecent News & Updates\nRecent updates\nSolid Earnings May Not Tell The Whole Story For Synektik Sp\u00f3lka Akcyjna (WSE:SNT)\nAug 15Is Now An Opportune Moment To Examine Synektik Sp\u00f3lka Akcyjna (WSE:SNT)?\nJan 21Cardiac marker could be a hit\nIn 5 years, the company should still be thriving, entering new markets and expanding in existing ones. Positive passage of the third stage of testing of a new cardiac marker could help. Due to the natSynektik Sp\u00f3lka Akcyjna's (WSE:SNT) 25% Price Boost Is Out Of Tune With Earnings\nSep 07Does Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Deserve A Spot On Your Watchlist?\nSep 03Synektik Sp\u00f3lka Akcyjna's (WSE:SNT) Performance Is Even Better Than Its Earnings Suggest\nAug 13Broker Revenue Forecasts For Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Are Surging Higher\nJun 29Why The 44% Return On Capital At Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Should Have Your Attention\nMar 13Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Looks Just Right With A 26% Price Jump\nFeb 15Here's Why We Think Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Might Deserve Your Attention Today\nFeb 08Solid Earnings Reflect Synektik Sp\u00f3lka Akcyjna's (WSE:SNT) Strength As A Business\nJan 26Estimating The Intrinsic Value Of Synektik Sp\u00f3lka Akcyjna (WSE:SNT)\nDec 15Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Has A Rock Solid Balance Sheet\nSep 12We Like Synektik Sp\u00f3lka Akcyjna's (WSE:SNT) Returns And Here's How They're Trending\nJun 22Is Now The Time To Put Synektik Sp\u00f3lka Akcyjna (WSE:SNT) On Your Watchlist?\nMay 23Is Synektik Sp\u00f3lka Akcyjna (WSE:SNT) A Risky Investment?\nOct 04Is Synektik Sp\u00f3lka Akcyjna (WSE:SNT) A Risky Investment?\nOct 27Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Is Posting Promising Earnings But The Good News Doesn\u2019t Stop There\nJun 22These 4 Measures Indicate That Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Is Using Debt Safely\nJun 10Does Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Have A Healthy Balance Sheet?\nMar 09Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Looks Like A Good Stock, And It's Going Ex-Dividend Soon\nFeb 13Does Synektik Sp\u00f3lka Akcyjna (WSE:SNT) Have A Place In Your Dividend Portfolio?\nJan 25Is Synektik Sp\u00f3lka Akcyjna's (WSE:SNT) Latest Stock Performance A Reflection Of Its Financial Health?\nDec 25Is Synektik Sp\u00f3lka Akcyjna (WSE:SNT) A Risky Investment?\nNov 30Shareholder Returns\n| SNT | PL Healthcare Services | PL Market | |\n|---|---|---|---|\n| 7D | 2.3% | 0.6% | -2.1% |\n| 1Y | 55.5% | 29.3% | 20.7% |\nReturn vs Industry: SNT exceeded the Polish Healthcare Services industry which returned 28.9% over the past year.\nReturn vs Market: SNT exceeded the Polish Market which returned 20.5% over the past year.\nPrice Volatility\n| SNT volatility | |\n|---|---|\n| SNT Average Weekly Movement | 6.4% |\n| Healthcare Services Industry Average Movement | 5.1% |\n| Market Average Movement | 4.7% |\n| 10% most volatile stocks in PL Market | 9.5% |\n| 10% least volatile stocks in PL Market | 2.9% |\nStable Share Price: SNT has not had significant price volatility in the past 3 months compared to the Polish market.\nVolatility Over Time: SNT's weekly volatility (6%) has been stable over the past year.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| 2001 | 203 | Cezary Kozanecki | www.synektik.com.pl |\nSynektik Sp\u00f3lka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland. The company sells medical equipment used in diagnostics and therapy, and nuclear medicine. It is also involved in development of IT solutions used in radiology, as well as researches, produces, and sells radiopharmaceutical products used in diagnostics for oncology.\nSynektik Sp\u00f3lka Akcyjna Fundamentals Summary\n| SNT fundamental statistics | |\n|---|---|\n| Market cap | z\u01421.90b |\n| Earnings (TTM) | z\u014292.64m |\n| Revenue (TTM) | z\u0142623.20m |\nIs SNT overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| SNT income statement (TTM) | |\n|---|---|\n| Revenue | z\u0142623.20m |\n| Cost of Revenue | z\u0142409.07m |\n| Gross Profit | z\u0142214.14m |\n| Other Expenses | z\u0142121.50m |\n| Earnings | z\u014292.64m |\nLast Reported Earnings\nJun 30, 2025\nNext Earnings Date\nn/a\n| Earnings per share (EPS) | 10.86 |\n| Gross Margin | 34.36% |\n| Net Profit Margin | 14.87% |\n| Debt/Equity Ratio | 3.0% |\nHow did SNT perform over the long term?\nSee historical performance and comparisonDividends\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/25 04:23 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/09/30 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nSynektik Sp\u00f3lka Akcyjna is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Kamil Kliszcz | Biuro maklerskie mBanku |\n| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |\n| Mateusz Krupa | Biuro maklerskie mBanku |"
    },
    {
      "url": "https://simplywall.st/company/id/c47ea9d4-3143-40e7-81a3-3dab1a02d3a5?utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo&blueprint=4014256",
      "text": "Oryzon Genomics (ORY) Stock Overview\nA clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 0/6 |\n| Future Growth | 5/6 |\n| Past Performance | 0/6 |\n| Financial Health | 6/6 |\n| Dividends | 0/6 |\nORY Community Fair Values\nSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.\nOryzon Genomics S.A. Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | \u20ac2.76 |\n| 52 Week High | \u20ac3.69 |\n| 52 Week Low | \u20ac1.40 |\n| Beta | 0.44 |\n| 1 Month Change | 0.18% |\n| 3 Month Change | 1.10% |\n| 1 Year Change | 57.25% |\n| 3 Year Change | 11.09% |\n| 5 Year Change | -4.34% |\n| Change since IPO | -40.11% |\nRecent News & Updates\nRecent updates\nWe Think The Compensation For Oryzon Genomics S.A.'s (BME:ORY) CEO Looks About Right\nJun 20Insufficient Growth At Oryzon Genomics S.A. (BME:ORY) Hampers Share Price\nFeb 13Growth Investors: Industry Analysts Just Upgraded Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts By 54%\nOct 03Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch\nJun 09Is Oryzon Genomics (BME:ORY) Using Too Much Debt?\nApr 04Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts\nJul 24Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?\nMay 01Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?\nFeb 26If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns\nJan 04Shareholder Returns\n| ORY | ES Biotechs | ES Market | |\n|---|---|---|---|\n| 7D | 3.6% | 2.1% | 0.9% |\n| 1Y | 57.2% | 1.4% | 28.2% |\nReturn vs Industry: ORY exceeded the Spanish Biotechs industry which returned 1.2% over the past year.\nReturn vs Market: ORY exceeded the Spanish Market which returned 28.1% over the past year.\nPrice Volatility\n| ORY volatility | |\n|---|---|\n| ORY Average Weekly Movement | 4.7% |\n| Biotechs Industry Average Movement | 8.0% |\n| Market Average Movement | 3.0% |\n| 10% most volatile stocks in ES Market | 6.3% |\n| 10% least volatile stocks in ES Market | 0.5% |\nStable Share Price: ORY's share price has been volatile over the past 3 months compared to the Spanish market.\nVolatility Over Time: ORY's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Spanish stocks.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| 2000 | 47 | Carlos Manuel Arjol | www.oryzon.com |\nOryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases.\nOryzon Genomics S.A. Fundamentals Summary\n| ORY fundamental statistics | |\n|---|---|\n| Market cap | \u20ac213.55m |\n| Earnings (TTM) | -\u20ac4.22m |\n| Revenue (TTM) | \u20ac7.47m |\nIs ORY overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| ORY income statement (TTM) | |\n|---|---|\n| Revenue | \u20ac7.47m |\n| Cost of Revenue | \u20ac278.96k |\n| Gross Profit | \u20ac7.19m |\n| Other Expenses | \u20ac11.41m |\n| Earnings | -\u20ac4.22m |\nLast Reported Earnings\nJun 30, 2025\nNext Earnings Date\nn/a\n| Earnings per share (EPS) | -0.054 |\n| Gross Margin | 96.27% |\n| Net Profit Margin | -56.48% |\n| Debt/Equity Ratio | 15.8% |\nHow did ORY perform over the long term?\nSee historical performance and comparisonCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/25 04:50 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nOryzon Genomics S.A. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Jyoti Prakash | Edison Investment Research |\n| Arron Aatkar | Edison Investment Research |\n| Joaquin Garcia-Quiros | JB Capital Markets |"
    },
    {
      "url": "https://simplywall.st/portfolio?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014256",
      "text": "US$294,170\nUS$186,967\n19.7%\nUS$129,548\nUS$46,631\nUS$11,515\n-US$726\nUS$4,776\n/yr\nPortfolio\nS&P 500 (US)\nA past performer with good growth potential\n14 holdings\n14\n| Symbol | Price Vs Fair Value | 7D Return | Total Return | Value & Cost | Weight & Shares | Avg. Price | 1Y chart | |\n|---|---|---|---|---|---|---|---|---|\nXOM Exxon Mobil | US$111.28 54.5% undervalued intrinsic discount | 4.3% +US$935 | 99.5% +US$12,919 | US$22,812 US$12,897 | 7.8% 205 | US$62.91 | ||\nTLX Telix Pharmaceuticals | AU$18.33 78.7% undervalued intrinsic discount | 3.3% +US$268 | 91.6% +US$6,712 | US$8,325 US$5,128 | 2.8% 700 | AU$11.00 | ||\nBAC Bank of America | US$49.48 18.4% undervalued intrinsic discount | 3.3% +US$936 | 68.6% +US$13,108 | US$29,688 US$19,100 | 10.1% 600 | US$31.83 | ||\nJNJ Johnson & Johnson | US$179.29 26.3% undervalued intrinsic discount | 1.7% +US$152 | 88.8% +US$4,529 | US$8,965 US$5,100 | 3.0% 50 | US$102.00 | ||\nJPM JPMorgan Chase | US$296.24 15.0% undervalued intrinsic discount | 1.6% +US$236 | 47.6% +US$4,997 | US$14,812 US$10,500 | 5.0% 50 | US$210.00 | ||\nTSLA Tesla | US$340.01 170.3% overvalued intrinsic discount | 1.4% +US$485 | 53.9% +US$11,901 | US$34,001 US$22,100 | 11.6% 100 | US$221.00 | ||\nBATS British American Tobacco | UK\u00a343.15 31.3% undervalued intrinsic discount | 1.3% +US$520 | 44.5% +US$17,162 | US$40,833 US$26,990 | 13.9% 700 | UK\u00a330.00 | ||\nOKTA Okta | US$92.05 28.3% undervalued intrinsic discount | 0.7% +US$53.60 | -54.0% -US$8,636 | US$7,364 US$16,000 | 2.5% 80 | US$200.00 | ||\nUNH UnitedHealth Group | US$307.42 64.6% undervalued intrinsic discount | -0.3% -US$21.40 | -25.2% -US$2,259 | US$6,148 US$8,960 | 2.1% 20 | US$448.00 | ||\nAMZN Amazon.com | US$228.84 17.2% undervalued intrinsic discount | -1.1% -US$151 | 64.5% +US$5,357 | US$13,044 US$7,775 | 4.4% 57 | US$136.41 | ||\nCRWD CrowdStrike Holdings | US$420.55 23.5% overvalued intrinsic discount | -1.4% -US$290 | 51.6% +US$9,333 | US$21,028 US$13,100 | 7.1% 50 | US$262.00 | ||\nMETA Meta Platforms | US$754.79 28.6% undervalued intrinsic discount | -1.6% -US$1,069 | 339.1% +US$53,785 | US$64,157 US$13,830 | 21.8% 85 | US$162.71 | ||\nNVDA NVIDIA | US$177.99 54.0% overvalued intrinsic discount | -2.2% -US$161 | 870.0% +US$15,096 | US$7,120 US$1,443 | 2.4% 40 | US$36.06 | ||\nPLTR Palantir Technologies | US$158.74 107.4% overvalued intrinsic discount | -8.8% -US$1,529 | 833.8% +US$14,174 | US$15,874 US$1,700 | 5.4% 100 | US$17.00 |\nThere are three easy ways to get started:\nSimply Wall St goes far beyond price tracking. You'll be able to:\nMost brokers and portfolio trackers only show prices and unrealised gains, with little context and lots of noisy news. Simply Wall St offers:\nIn short, Simply Wall St is more than a tracker \u2014 it's a complete investing platform for monitoring, analysing, and growing your portfolio.\nHave feedback on the portfolio tool?"
    },
    {
      "url": "https://simplywall.st/company/id/dd17423e-9c88-41ae-8c34-5047e7a2ea7f?utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo&blueprint=4014256",
      "text": "LINK Mobility Group Holding (LINK) Stock Overview\nProvides mobile and communication-platform-as-a-service solutions. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 3/6 |\n| Future Growth | 4/6 |\n| Past Performance | 1/6 |\n| Financial Health | 6/6 |\n| Dividends | 0/6 |\nLINK Community Fair Values\nSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.\nLINK Mobility Group Holding ASA Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | NOK 33.15 |\n| 52 Week High | NOK 36.20 |\n| 52 Week Low | NOK 19.38 |\n| Beta | 1.14 |\n| 1 Month Change | 7.63% |\n| 3 Month Change | 31.55% |\n| 1 Year Change | 56.74% |\n| 3 Year Change | 332.49% |\n| 5 Year Change | n/a |\n| Change since IPO | -38.61% |\nRecent News & Updates\nRecent updates\nLINK Mobility Group Holding ASA's (OB:LINK) P/E Is On The Mark\nAug 10LINK Mobility Group Holding ASA's (OB:LINK) Price In Tune With Earnings\nApr 17Is There An Opportunity With LINK Mobility Group Holding ASA's (OB:LINK) 47% Undervaluation?\nMar 11LINK Mobility Group Holding's (OB:LINK) Performance Is Even Better Than Its Earnings Suggest\nFeb 21Is LINK Mobility Group Holding (OB:LINK) Using Too Much Debt?\nFeb 15AI-driven SaaS Expansion Into Europe May Boost Future Earnings, But Volatility Remains A Concern\nExpansion into less penetrated European markets and terminating low-margin contracts may drive future revenue and improve net margins.An Intrinsic Calculation For LINK Mobility Group Holding ASA (OB:LINK) Suggests It's 28% Undervalued\nNov 06LINK Mobility Group Holding's (OB:LINK) Earnings Are Of Questionable Quality\nAug 22LINK Mobility Group Holding (OB:LINK) Seems To Use Debt Quite Sensibly\nAug 16These 4 Measures Indicate That LINK Mobility Group Holding (OB:LINK) Is Using Debt Reasonably Well\nFeb 02Is Now An Opportune Moment To Examine LINK Mobility Group Holding ASA (OB:LINK)?\nJan 25Shareholders Can Be Confident That LINK Mobility Group Holding's (OB:LINK) Earnings Are High Quality\nAug 23Are Investors Undervaluing LINK Mobility Group Holding ASA (OB:LINK) By 39%?\nAug 05Earnings Release: Here's Why Analysts Cut Their LINK Mobility Group Holding ASA (OB:LINK) Price Target To kr27.00\nFeb 13Industry Analysts Just Made An Upgrade To Their LINK Mobility Group Holding ASA (OB:LINK) Revenue Forecasts\nAug 18Calculating The Intrinsic Value Of LINK Mobility Group Holding ASA (OB:LINK)\nJul 18Shareholder Returns\n| LINK | NO Software | NO Market | |\n|---|---|---|---|\n| 7D | -6.2% | -3.4% | 2.1% |\n| 1Y | 56.7% | 30.3% | 7.7% |\nReturn vs Industry: LINK exceeded the Norwegian Software industry which returned 30.3% over the past year.\nReturn vs Market: LINK exceeded the Norwegian Market which returned 7.7% over the past year.\nPrice Volatility\n| LINK volatility | |\n|---|---|\n| LINK Average Weekly Movement | 4.9% |\n| Software Industry Average Movement | 6.2% |\n| Market Average Movement | 4.7% |\n| 10% most volatile stocks in NO Market | 11.4% |\n| 10% least volatile stocks in NO Market | 2.7% |\nStable Share Price: LINK has not had significant price volatility in the past 3 months compared to the Norwegian market.\nVolatility Over Time: LINK's weekly volatility (5%) has been stable over the past year.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| 2001 | 678 | Thomas Berge | www.linkmobility.com |\nLINK Mobility Group Holding ASA, together with its subsidiaries, provides mobile and communication-platform-as-a-service solutions. It operates through four segments: Northern Europe, Western Europe, Central Europe, and Global Messaging. The company provides Xenioo, a platform to automate conversations between companies and people across a range of text and voice channels; a marketing platform that offers customer engagement, marketing automation, and email and SMS marketing services; long numbers that sends and receives messages; and short codes, a memorable short mobile number to allow inbound communications to flow.\nLINK Mobility Group Holding ASA Fundamentals Summary\n| LINK fundamental statistics | |\n|---|---|\n| Market cap | NOK 9.41b |\n| Earnings (TTM) | NOK 108.60m |\n| Revenue (TTM) | NOK 6.92b |\nIs LINK overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| LINK income statement (TTM) | |\n|---|---|\n| Revenue | NOK 6.92b |\n| Cost of Revenue | NOK 5.71b |\n| Gross Profit | NOK 1.21b |\n| Other Expenses | NOK 1.10b |\n| Earnings | NOK 108.60m |\nLast Reported Earnings\nJun 30, 2025\nNext Earnings Date\nNov 05, 2025\n| Earnings per share (EPS) | 0.38 |\n| Gross Margin | 17.44% |\n| Net Profit Margin | 1.57% |\n| Debt/Equity Ratio | 49.3% |\nHow did LINK perform over the long term?\nSee historical performance and comparisonCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/25 04:29 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nLINK Mobility Group Holding ASA is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| null null | ABG Sundal Collier |\n| Mads Strom | Danske Bank |\n| Rayan Sayyah | Danske Bank |"
    },
    {
      "url": "https://simplywall.st/discover/investing-ideas/152/undiscovered-gems-with-strong-fundamentals/global?utm_medium=finance_user&utm_campaign=conclusion-grid&utm_source=yahoo&blueprint=4014256",
      "text": "Results\n4655\nHigh-performing small cap companies that haven't yet garnered significant analyst attention, and could lead to superior returns.\n4655 companies\nAesler Grup Internasional\nMarket Cap: Rp3.7t\nProvides architectural and construction management services in Indonesia.\nRONY\nRp2,990.00\n7D\n0%\n1Y\n1,310.4%\nXinjiang Torch Gas\nMarket Cap: CN\u00a53.1b\nOperates as a gas service company in China.\n603080\nCN\u00a521.85\n7D\n-1.8%\n1Y\n67.4%\nShandong Sinoglory Health Food\nMarket Cap: CN\u00a52.3b\nManufactures soy proteins in China.\n603182\nCN\u00a514.20\n7D\n-0.2%\n1Y\n43.1%\nShanghai Material Trading\nMarket Cap: CN\u00a55.3b\nEngages in the wholesale and retail of production materials for automobile and chemicals in China and internationally.\n600822\nCN\u00a512.57\n7D\n4.8%\n1Y\n70.6%\nConcord Enviro Systems\nMarket Cap: \u20b911.4b\nEngages in the design, manufacture, installation, operation, and maintenance of industrial water and wastewater treatment, and reuse and zero liquid discharge systems and plants.\nCEWATER\n\u20b9550.50\n7D\n7.1%\n1Y\nn/a\nHangzhou Xili Intelligent TechnologyLtd\nMarket Cap: CN\u00a52.5b\nHangzhou Xili Intelligent Technology Co.,Ltd.\n688616\nCN\u00a514.24\n7D\n2.2%\n1Y\n76.0%\nRenxin New MaterialLtd\nMarket Cap: CN\u00a53.0b\nEngages in the research and development, production, and sale of polystyrene polymer materials in China.\n301395\nCN\u00a512.54\n7D\n2.7%\n1Y\n71.0%\nZHEJIANG DIBAY ELECTRICLtd\nMarket Cap: CN\u00a53.0b\nEngages in the research and development, production, and sale of sealed motors for household, commercial, and vehicle compressors in China and internationally.\n603320\nCN\u00a520.35\n7D\n4.7%\n1Y\n67.4%\nGuangdong Delian Group\nMarket Cap: CN\u00a54.1b\nEngages in the automobile fine chemicals, automobile sales service, and automobile repair and maintenance businesses, and development of new application scenarios in China.\n002666\nCN\u00a55.33\n7D\n2.7%\n1Y\n59.6%\nOriental Precision & EngineeringLtd\nMarket Cap: \u20a9298.3b\nOriental Precision & Engineering Co.,Ltd.\nA014940\n\u20a96,550.00\n7D\n-4.7%\n1Y\n57.1%\nYashima Denki\nMarket Cap: JP\u00a546.4b\nProvides plant business, industry/equipment, and transportation business in Japan and internationally.\n3153\nJP\u00a52,180.00\n7D\n8.7%\n1Y\n39.5%\nHind Rectifiers\nMarket Cap: \u20b928.4b\nDesigns, develops, manufactures, and markets power semiconductors, power electronic equipment, and railway transportation equipment in India and internationally.\n504036\n\u20b91,652.35\n7D\n-13.7%\n1Y\n71.6%\nJinsanjiang (Zhaoqing) Silicon Material\nMarket Cap: CN\u00a52.8b\nEngages in the research and development, production, and sale of precipitated silica.\n301059\nCN\u00a512.27\n7D\n1.1%\n1Y\n50.4%\nMinmetals Development\nMarket Cap: CN\u00a59.9b\nEngages in resource trading, metal trading, and supply chain services in China and internationally.\n600058\nCN\u00a59.22\n7D\n11.9%\n1Y\n55.0%\nTech Semiconductors\nMarket Cap: CN\u00a511.1b\nEngages in the development, manufacture, and sale of power semiconductor devices in China.\n300046\nCN\u00a546.93\n7D\n2.5%\n1Y\n202.8%\nManpowerGroup Greater China\nMarket Cap: HK$1.2b\nAn investment holding company, provides workforce solutions and services in the People\u2019s Republic of China, Hong Kong, Macau, and Taiwan.\n2180\nHK$5.70\n7D\n-0.9%\n1Y\n23.9%\nChongqing Chuanyi Automation\nMarket Cap: CN\u00a510.9b\nResearches, manufactures, and markets industrial auto-control systems and devices, and engineering integration services in China.\n603100\nCN\u00a521.38\n7D\n4.6%\n1Y\n33.8%\nZhubo Design\nMarket Cap: CN\u00a52.8b\nEngages in architectural design and consulting services in China.\n300564\nCN\u00a517.27\n7D\n0.3%\n1Y\n87.7%\nNanfang Ventilator\nMarket Cap: CN\u00a55.2b\nDesigns and manufactures HVAC products in China.\n300004\nCN\u00a510.75\n7D\n28.3%\n1Y\n166.1%\nHangzhou Fortune Gas Cryogenic Group\nMarket Cap: CN\u00a57.6b\nHangzhou Fortune Gas Cryogenic Group Co., Ltd.\n603173\nCN\u00a547.85\n7D\n5.8%\n1Y\n167.2%\nItafos\nMarket Cap: CA$572.0m\nOperates as a phosphate and specialty fertilizer company.\nIFOS\nCA$2.96\n7D\n0%\n1Y\n82.7%\nWholetech System Hitech\nMarket Cap: NT$9.4b\nProvides system integration services in Taiwan, China, and Singapore.\n3402\nNT$129.00\n7D\n4.0%\n1Y\n16.7%\nDaoming Optics&ChemicalLtd\nMarket Cap: CN\u00a56.2b\nEngages in the research and development, production, and sale of reflective materials and products worldwide.\n002632\nCN\u00a59.89\n7D\n5.1%\n1Y\n48.1%\nLelon Electronics\nMarket Cap: NT$14.0b\nDevelops, manufactures, markets, trades in, and sells electrolytic capacitors worldwide.\n2472\nNT$85.00\n7D\n2.2%\n1Y\n9.3%\nLi Ming Development Construction\nMarket Cap: NT$4.3b\nLi Ming Development Construction Co., Ltd.\n6212\nNT$41.95\n7D\n1.7%\n1Y\n-57.0%\nJiangsu Rainbow Heavy Industries\nMarket Cap: CN\u00a56.3b\nJiangsu Rainbow Heavy Industries Co., Ltd.\n002483\nCN\u00a57.10\n7D\n-0.8%\n1Y\n78.4%\nSuzhou Longjie Special Fiber\nMarket Cap: CN\u00a53.4b\nEngages in the research and development, production, and sale of polyester filaments in China and internationally.\n603332\nCN\u00a516.08\n7D\n13.1%\n1Y\n133.7%\nChina New City Group\nMarket Cap: HK$1.6b\nAn investment holding company, engages in the commercial property development and investment for leasing, and commercial operations in Mainland China and internationally.\n1321\nHK$0.85\n7D\n-12.4%\n1Y\n6.3%\nShanghai Chlor-Alkali Chemical\nMarket Cap: CN\u00a59.8b\nManufactures and sells chemical products in China and internationally.\n600618\nCN\u00a510.58\n7D\n3.5%\n1Y\n36.9%\nNeosem\nMarket Cap: \u20a9336.6b\nManufactures and sells semiconductor inspection equipment.\nA253590\n\u20a97,920.00\n7D\n-9.2%\n1Y\n-21.2%\nOuro Fino Sa\u00fade Animal Participa\u00e7\u00f5es\nMarket Cap: R$1.2b\nEngages in the development, production, and sale of veterinary drugs, vaccines, and other products for production and companion animals primarily in Brazil.\nOFSA3\nR$22.22\n7D\n-4.8%\n1Y\n-2.1%\nTimex Group India\nMarket Cap: \u20b928.0b\nEngages in designing, manufacturing, and trading of watches in India and internationally.\n500414\n\u20b9277.60\n7D\n0.5%\n1Y\n82.7%\nJagsonpal Pharmaceuticals\nMarket Cap: \u20b915.7b\nEngages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally.\nJAGSNPHARM\n\u20b9235.05\n7D\n-4.1%\n1Y\n55.3%\nShenzhen Bsc TechnologyLtd\nMarket Cap: CN\u00a56.8b\nEngages in the design, development, production, and sale of functional devices for electronic products.\n300951\nCN\u00a540.27\n7D\n8.2%\n1Y\n55.5%\nSociete de Limonaderies et de Boissons Rafraichissantes d'Afrique\nMarket Cap: XOF 307.7b\nEngages in the manufacture and sale of beer, soft drinks, mineral water, alcomixes, and energy drink products.\nSLBC\nXOF 18,690.00\n7D\n5.9%\n1Y\nn/a\nLemtech Holdings\nMarket Cap: NT$5.2b\nResearch, develops, produces, and sells precision metal dies and metal stampings in Asia, the Americas, and Europe.\n4912\nNT$79.50\n7D\n-1.6%\n1Y\n-19.3%"
    },
    {
      "url": "https://simplywall.st/discover/investing-ideas/215171/high-growth-tech-and-ai-stocks/global?utm_medium=finance_user&utm_campaign=conclusion-grid&utm_source=yahoo&blueprint=4014256",
      "text": "Results\n347\nCompanies within the technology and artificial intelligence (AI) sector, that exhibit significant growth potential, providing opportunities to capitalize on the rapid advancement and innovation within the industry.\n347 companies\nGold Circuit Electronics\nMarket Cap: NT$223.4b\nDesigns, manufactures, processes, and distributes printed circuit boards in Taiwan.\n2368\nNT$459.00\n7D\n-1.4%\n1Y\n112.5%\nShengyi Electronics\nMarket Cap: CN\u00a553.1b\nEngages in the research and development, production, and sales of various printed circuit boards in China.\n688183\nCN\u00a565.10\n7D\n18.6%\n1Y\n230.8%\nCARsgen Therapeutics Holdings\nMarket Cap: HK$11.7b\nAn investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.\n2171\nHK$21.06\n7D\n-7.2%\n1Y\n469.2%\neWeLLLtd\nMarket Cap: JP\u00a543.0b\nDevelops business support cloud services for visiting nursing stations in Japan.\n5038\nJP\u00a52,840.00\n7D\n3.7%\n1Y\n84.4%\nCD Projekt\nMarket Cap: z\u014225.8b\nTogether its subsidiaries, engages in the development, publishing, and digital distribution of video games for personal computers and video game consoles in Poland.\nCDR\nz\u0142257.90\n7D\n1.1%\n1Y\n43.1%\nKebNi\nMarket Cap: SEK 688.7m\nDevelops, produces, and sells products and applications for stabilization, navigation, and satcom worldwide.\nKEBNI B\nSEK 2.54\n7D\n17.1%\n1Y\n76.6%\nIntellego Technologies\nMarket Cap: SEK 4.8b\nManufactures and sells colorimetric ultraviolet indicators in Sweden.\nINT\nSEK 155.00\n7D\n5.6%\n1Y\n491.6%\nFositek\nMarket Cap: NT$71.3b\nEngages in the designing and manufacturing services for various metal stamping products.\n6805\nNT$1,040.00\n7D\n-1.9%\n1Y\n25.3%\nTips Music\nMarket Cap: \u20b974.3b\nEngages in the acquisition and exploitation of music rights in India and internationally.\nTIPSMUSIC\n\u20b9581.60\n7D\n-1.1%\n1Y\n-23.2%\nHacksaw\nMarket Cap: SEK 20.2b\nOperates as a B2B technology platform and game development company.\nHACK\nSEK 69.78\n7D\n1.1%\n1Y\nn/a\nEcho IQ\nMarket Cap: AU$139.1m\nProvides artificial intelligence (AI) diagnostics tool that enhance the diagnosis of structural heart disease in Australia and the United Kingdom.\nEIQ\nAU$0.21\n7D\n1.2%\n1Y\n38.7%\nFoxconn Industrial Internet\nMarket Cap: CN\u00a5910.2b\nDesigns and manufactures communication network and cloud computing equipment, precision tools, and industrial solutions.\n601138\nCN\u00a545.83\n7D\n2.2%\n1Y\n124.0%\nSystems\nMarket Cap: PK\u20a8206.6b\nEngages in the software development and trading, hardware, and business process outsourcing (BPO) service businesses in Pakistan, North America, the Middle East, Africa, Europe, the Asia Pacific, and internationally.\nSYS\nPK\u20a8140.61\n7D\n2.7%\n1Y\n67.1%\nPharmaEssentia\nMarket Cap: NT$163.5b\nA biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally.\n6446\nNT$490.50\n7D\n-2.7%\n1Y\n-28.6%\nEoptolink Technology\nMarket Cap: CN\u00a5271.7b\nEngages in the research and development, production and sales of optical modules in China and internationally.\n300502\nCN\u00a5273.81\n7D\n17.4%\n1Y\n287.2%\nBonesupport Holding\nMarket Cap: SEK 19.5b\nAn orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally.\nBONEX\nSEK 296.00\n7D\n4.4%\n1Y\n-0.9%\nALTEOGEN\nMarket Cap: \u20a922.6t\nA bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.\nA196170\n\u20a9422,000.00\n7D\n-3.4%\n1Y\n34.0%\nAccton Technology\nMarket Cap: NT$525.4b\nResearches and develops, manufactures, and sells network communication equipment in Taiwan, America, rest of Asia, Europe, and internationally.\n2345\nNT$940.00\n7D\n-9.2%\n1Y\n82.5%\nNaruida Technology\nMarket Cap: CN\u00a514.3b\nManufactures and sells polarized multifunctional active phased array radars in China.\n688522\nCN\u00a547.29\n7D\n4.1%\n1Y\n64.8%\nShelly Group\nMarket Cap: \u20ac984.2m\nEngages in development, production, and sale of internet of things devices.\nSLYG\n\u20ac54.20\n7D\n4.2%\n1Y\n51.4%\nBlinkLab\nMarket Cap: AU$60.7m\nFocuses on the development and commercialization of intellectual property related to smartphone-neurobehavioral testing.\nBB1\nAU$0.48\n7D\n-4.0%\n1Y\n125.6%\nZhejiang Meorient Commerce Exhibition\nMarket Cap: CN\u00a54.7b\nZhejiang Meorient Commerce Exhibition Inc.\n300795\nCN\u00a516.00\n7D\n5.1%\n1Y\n52.6%\nUgreen Group\nMarket Cap: CN\u00a527.9b\nEngages in the research, development, design, production, and sale of consumer electronic products in China and internationally.\n301606\nCN\u00a567.14\n7D\n-2.4%\n1Y\n133.4%\nargenx\nMarket Cap: \u20ac34.6b\nA commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.\nARGX\n\u20ac565.60\n7D\n2.1%\n1Y\n21.7%\nT&S CommunicationsLtd\nMarket Cap: CN\u00a526.9b\nDevelops, manufactures, and sells fiber optics communication products in China.\n300570\nCN\u00a5120.97\n7D\n1.1%\n1Y\n305.1%\nXiamen Amoytop Biotech\nMarket Cap: CN\u00a534.7b\nEngages in research, development, production, and sale of recombinant protein drugs in China.\n688278\nCN\u00a585.30\n7D\n-0.4%\n1Y\n55.1%\nMereo BioPharma Group\nMarket Cap: US$270.5m\nA biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.\nMREO\nUS$1.70\n7D\n-2.3%\n1Y\n-64.8%\nAsia Vital Components\nMarket Cap: NT$399.8b\nProvides thermal solutions worldwide.\n3017\nNT$1,030.00\n7D\n-3.7%\n1Y\n68.3%\nNewborn Town\nMarket Cap: HK$13.6b\nAn investment holding company, engages in the social networking business worldwide.\n9911\nHK$10.13\n7D\n-0.2%\n1Y\n269.7%\nPalantir Technologies\nMarket Cap: US$376.6b\nPalantir Technologies Inc. builds and deploys software platforms for the intelligence community to assist in counterterrorism investigations and operations in the United States, the United Kingdom, and internationally.\nPLTR\nUS$158.74\n7D\n-8.8%\n1Y\n414.6%\nVanda Pharmaceuticals\nMarket Cap: US$280.7m\nA biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.\nVNDA\nUS$4.75\n7D\n8.9%\n1Y\n-13.0%\nMedical Data Vision\nMarket Cap: JP\u00a521.8b\nDevelops, produces, maintains, and sells medical information integration systems in Japan.\n3902\nJP\u00a5575.00\n7D\n4.9%\n1Y\n8.9%\nElectric Connector Technology\nMarket Cap: CN\u00a521.0b\nEngages in the research, design, development, manufacture, and sale of micro electronic connectors and interconnection system related products in China, North America, Europe, Japan, Asia Pacific, and internationally.\n300679\nCN\u00a550.08\n7D\n6.2%\n1Y\n60.8%\nChengdu Zhimingda Electronics\nMarket Cap: CN\u00a56.3b\nProvides customized embedded modules and solutions in China.\n688636\nCN\u00a537.33\n7D\n1.0%\n1Y\n188.3%\nOS Therapies\nMarket Cap: US$79.1m\nA clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.\nOSTX\nUS$2.48\n7D\n20.4%\n1Y\n-40.2%\nAldeyra Therapeutics\nMarket Cap: US$348.0m\nA biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.\nALDX\nUS$5.81\n7D\n7.8%\n1Y\n4.3%"
    }
  ],
  "argos_summary": "The European STOXX 600 rose 1.40% amid optimism about U.S. rate cuts and stronger eurozone business activity, prompting a search for high\u2011growth tech and AI stocks. Oryzon Genomics, a clinical\u2011stage biopharma focused on epigenetics, shows strong revenue and earnings growth prospects but remains unprofitable with high debt, while LINK Mobility Group Holding reports robust earnings growth and expanding SaaS revenue, though its net margin is modest. Synektik Sp\u00f3lka Akcyjna, a Polish healthcare services firm, demonstrates impressive earnings and revenue growth, high return on equity, and solid financial health, positioning it as a standout performer in the sector. These companies illustrate the mix of promising growth potential and current financial challenges within Europe\u2019s high\u2011growth tech landscape.",
  "argos_id": "FRD083BTK"
}